Free Trial

UroGen Pharma (URGN) News Today

UroGen Pharma logo
$14.40 +0.07 (+0.45%)
As of 12:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Why is UroGen Pharma Up Today?

UroGen Pharma Ltd. (URGN) shares have experienced heightened trading activity following several analyst upgrades and price target increases, even as a flood of class‐action and investor‐alert announcements raises legal overhang concerns.

  • HC Wainwright upgraded URGN from “neutral” to “buy” with a $50.00 price target (implying ~256% upside).
  • American Banking & News reports raised URGN price targets to $30.00 and $47.00.
  • Short interest in URGN fell 29.9% in May, potentially reducing bearish pressure.
  • Unusually high trading volume observed after analyst upgrade, reflecting elevated investor interest.
  • Multiple law firms (Pomerantz, BFA Law, Levi & Korsinsky, Schall, Bernstein Liebhard, Bronstein Gewirtz & Grossman, The Gross Law Firm) filed or reminded investors of pending securities‐fraud class actions against URGN and its executives.
Posted 59m agoAI Generated. May Contain Errors.

URGN Latest News

UroGen Pharma Ltd. stock logo
UroGen Pharma Ltd. (NASDAQ:URGN) Short Interest Down 29.9% in May
UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) was the recipient of a large decrease in short interest in May. As of May 31st, there was short interest totalling 3,920,000 shares, a decrease of 29.9% from the May 15th total of 5,590,000 shares. Based on an average daily trading volume, of 1,670,000 shares, the days-to-cover ratio is currently 2.3 days. Approximately 17.6% of the shares of the company are sold short.
UroGen Pharma Ltd. stock logo
UroGen Pharma (NASDAQ:URGN) Sees Large Volume Increase Following Analyst Upgrade
UroGen Pharma (NASDAQ:URGN) Sees Unusually-High Trading Volume After Analyst Upgrade
UroGen Pharma Ltd. stock logo
UroGen Pharma (NASDAQ:URGN) Stock Rating Upgraded by HC Wainwright
HC Wainwright raised UroGen Pharma from a "neutral" rating to a "buy" rating and set a $50.00 price target for the company in a research note on Monday.
UroGen Pharma Ltd. stock logo
SG Americas Securities LLC Buys 142,245 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)
SG Americas Securities LLC grew its stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 701.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 162,514 shares of the company's stock after acquiring an a
UroGen Pharma (NASDAQ:URGN) Price Target Raised to $30.00
UroGen Pharma (NASDAQ:URGN) Price Target Raised to $47.00
UroGen Pharma (NASDAQ:URGN) Shares Gap Up on Analyst Upgrade
UroGen Pharma Ltd. stock logo
Scotiabank Forecasts Strong Price Appreciation for UroGen Pharma (NASDAQ:URGN) Stock
Scotiabank boosted their price target on shares of UroGen Pharma from $23.00 to $47.00 and gave the stock a "sector outperform" rating in a research report on Friday.
UroGen Pharma: Lessons Learned And Future Outlook
UroGen Pharma Ltd. stock logo
UroGen Pharma (NASDAQ:URGN) Shares Gap Up Following Analyst Upgrade
UroGen Pharma (NASDAQ:URGN) Shares Gap Up on Analyst Upgrade
UroGen Pharma Ltd. stock logo
Guggenheim Forecasts Strong Price Appreciation for UroGen Pharma (NASDAQ:URGN) Stock
Guggenheim boosted their price objective on UroGen Pharma from $15.00 to $30.00 and gave the stock a "buy" rating in a research report on Friday.
UroGen Pharma Ltd. stock logo
UroGen Pharma's (URGN) Buy Rating Reaffirmed at D. Boral Capital
D. Boral Capital reiterated a "buy" rating and issued a $25.00 target price on shares of UroGen Pharma in a research report on Thursday.
UroGen Pharma Ltd. stock logo
UroGen Pharma Ltd. (NASDAQ:URGN) Insider Mark Schoenberg Sells 5,162 Shares
UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 5,162 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $7.37, for a total transaction of $38,043.94. Following the completion of the transaction, the insider now owns 153,378 shares in the company, valued at approximately $1,130,395.86. This trade represents a 3.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.
Get UroGen Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.

URGN Media Mentions By Week

URGN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

URGN
News Sentiment

0.18

0.90

Average
Medical
News Sentiment

URGN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

URGN Articles
This Week

57

6

URGN Articles
Average Week

Get UroGen Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:URGN) was last updated on 6/17/2025 by MarketBeat.com Staff
From Our Partners